Zai Lab expects about $250 million from a new share sale for drug projects and general costs, but existing owners will hold a smaller share of the company. The filing reports no new drug results or estimate of its cash needs, so neither fact clearly outweighs the other.
The cash gives Zai Lab more money to develop its drug projects and cover general costs. New shares also leave current owners with a smaller piece of the company. The filing gives no cash-needs estimate or new drug results, so these facts do not clearly point one way.
Follow Zai Lab Ltd (ZLAB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ZLAB